Generic Emsam Availability
Emsam is a brand name of selegiline, approved by the FDA in the following formulation(s):
EMSAM (selegiline - film, extended release;transdermal)
-
Manufacturer: SOMERSET
Approval date: February 27, 2006
Strength(s): 6MG/24HR [RLD], 9MG/24HR, 12MG/24HR
Has a generic version of Emsam been approved?
No. There is currently no therapeutically equivalent version of Emsam available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Emsam. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Adhesive mixture for transdermal delivery of highly plasticizing drugs
Patent 7,070,808
Issued: July 4, 2006
Inventor(s): Govil; Sharad K. & Weimann; Ludwig J.
Assignee(s): Mylan Technologies, Inc.
Transdermal drug delivery patches and methods of their production are described. The patches can be made such that the accommodate highly plasticizing drugs such as selegiline and/or the use of protonated forms of various drugs.Patent expiration dates:- May 10, 2018✓✓
- May 10, 2018
-
Adhesive mixture for transdermal delivery of highly plasticizing drugs
Patent 7,150,881
Issued: December 19, 2006
Inventor(s): Govil; Sharad K. & Weimann; Ludwig J.
Assignee(s): Mylan Technologies, Inc.
Transdermal drug delivery patches and methods of their production are described. The patches can be made such that the accommodate highly plasticizing drugs such as selegiline and/or the use of protonated forms of various drugs.Patent expiration dates:- June 12, 2018✓✓
- June 12, 2018
-
Adhesive mixture for transdermal delivery of highly plasticizing drugs
Patent 7,638,140
Issued: December 29, 2009
Inventor(s): Govil; Sharad K. & Weimann; Ludwig J.
Assignee(s): Mylan Technologies, Inc.
Transdermal drug delivery patches and methods of their production are described. The patches can be made such that the accommodate highly plasticizing drugs such as selegiline and/or the use of protonated forms of various drugs.Patent expiration dates:- May 10, 2018✓
- May 10, 2018
More about Emsam (selegiline)
Consumer resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
